ESC TV Today – Your Cardiovascular News

Host: Emer Joyce Guest: Fleur Tjong Want to watch that extended interview on https://esc365.escardio.org/event/2528?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

This episode covers: Cardiology This Week: A concise summary of recent studies What´s new in TAVI? Digital solutions in arrhythmias Mythbusters - Gratitude is heart healthy Host: Emer Joyce Guests: JP Carpenter, Davide Capodanno, Fleur Tjong Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Want to watch that extended interview on Digital solutions in arrhythmias, go to: https://esc365.escardio.org/event/2528?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

In this engaging discussion, Steffen Massberg, a leading cardiologist from Ludwig Maximilians University Hospital, dives into dual antiplatelet therapy (DAPT). He highlights how about 40% of patients meet high bleeding risk criteria and discusses the implications for shortening DAPT duration. Massberg reviews evidence from key trials supporting shorter therapies and emphasizes the importance of individualized strategies. He also addresses barriers like physician fears regarding stent thrombosis while advocating for advanced imaging techniques to enhance decision-making in DAPT.

Steffen Massberg, a cardiology expert, discusses the nuances of dual antiplatelet therapy duration and strategies tailored for high bleeding-risk patients. He emphasizes the safety of shorter DAPT in complex cases. Joining him is Prash Sanders, a cardiac electrophysiologist, who delves into the obesity-related mechanisms that contribute to atrial fibrillation, highlighting the significance of weight loss thresholds for reducing AF risk. Both guests stress the importance of proactive risk management in improving heart health outcomes.

Folkert Asselbergs, Professor of Cardiology and digital health expert, dives into the transformative role of large language models in clinical settings. He discusses how these models can automate administrative tasks and even serve as AI companions grounded in ESC guidelines. Folkert addresses concerns about hallucinations and bias, and argues for innovative evaluation methods over traditional trials. He encourages democratized patient access to AI tools while emphasizing data security and the potential for personal health apps in the future.

Folkert Asselbergs, a cardiologist and expert in digital health and AI, discusses the implications of large language models (LLMs) in clinical settings, including their role in patient engagement and reducing clinician workload. Massimo Imazio, chair of the upcoming ESC guidelines on myocarditis, delves into the nuances of diagnosing myocarditis, emphasizing cardiac MRI and biopsies when necessary. He also provides critical insights on managing immune-related myocarditis and guidelines for returning patients to physical activity.

In this insightful discussion, Erik Stroes, an academic clinician from Amsterdam University Medical Center with expertise in lipid disorders, delves into the significance of Lp(a) in cardiovascular health. He highlights how elevated Lp(a) is prevalent yet often overlooked in risk assessments. Erik explains the limited impact of lifestyle changes and current medications on lowering Lp(a), and he emphasizes the need for routine testing to enhance risk prediction. He also shares insights on the clinical significance of Lp(a)-lowering therapies and their prioritization in high-risk patients.

Erik Stroes, a leading cardiologist from Amsterdam, dives into the intricate biology of Lp(a) and highlights emerging therapies set to transform cardiovascular care. Vijay Kunadian, an expert in treating older and frail patients, discusses nuanced management strategies for myocardial infarction. They debate the importance of screening for Lp(a) and weigh the benefits of invasive versus conservative approaches for older adults. JP Carpenter contributes a witty 'Mythbusters' segment, debunking common beliefs about beetroot’s impact on heart health.

In this engaging discussion, cardiology specialist Stephanie Schwarting, affiliated with renowned institutions in Munich and Heidelberg, shares her expertise on arrhythmias within cardiac amyloidosis. She delves into the complexities of rate control influenced by heart rate dependence and autonomic dysfunction. The conversation covers the challenges of ablation based on disease stage and the unpredictable progression of conduction disease. Schwarting also emphasizes the importance of individualized monitoring strategies and the role of multidisciplinary teams in enhancing patient care.

Stephanie Schwarting, a cardiac amyloidosis expert from University Hospital Munich, dives into arrhythmias in transthyretin cardiac amyloidosis, discussing management strategies and the nuances of treating atrial fibrillation in this context. Ahmad Masri, a cardiologist specializing in hypertrophic cardiomyopathy from Oregon Health & Science University, explores the complexities of managing LVOT obstruction and the role of myosin inhibitors versus traditional therapies. Both guests provide invaluable insights into cutting-edge treatments and patient management approaches.